Fairvalue-Calculator Fairvalue-Calculator
EN DE

Emcure Pharmaceuticals Limited (EMCURE) Fair Value & Analysis

Healthcare · IN · Market cap ₹358B

Price₹1,880
Fair Value₹974.65
Upside-48.2%
Quality96/100
Evidence: High Range ₹587.22 – ₹1,463

Fair value as of: Jun 29, 2026

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

Emcure Pharmaceuticals Limited (EMCURE) currently trades at ₹1,880, while our model-based Fair Value estimate is ₹974.65 — implying the stock looks roughly 48.2% overvalued today. We read business quality at 96/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglutide injection for weight loss. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.

Open the full interactive analysis →

Similar stocks

Jiangsu Hengrui Pharmaceuticals Co (600276) -46% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -74% Hansoh Pharmaceutical Group (3692) -47% Divi's Laboratories Limited (DIVISLAB) -70% Swedish Orphan Biovitrum AB (SOBI) -48%

Frequently asked questions

Is Emcure Pharmaceuticals Limited (EMCURE) undervalued?
As of Jun 29, 2026, our model estimates a fair value of ₹974.65 versus a price of ₹1,880 — about −48% (overvalued). Model-based estimate, not financial advice.
What is the fair value of EMCURE?
Our 21-model fair value for Emcure Pharmaceuticals Limited is ₹974.65 (as of Jun 29, 2026), built from audited fundamentals. The current price is ₹1,880.
What is the quality score of EMCURE?
Emcure Pharmaceuticals Limited has a Quality Score of 96/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.